Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Revenue (2020 - 2026)

Insight Molecular Diagnostics' Revenue history spans 6 years, with the latest figure at $1.1 million for Q4 2025.

  • On a quarterly basis, Revenue fell 23.35% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 115.58% increase, with the full-year FY2025 number at $4.1 million, up 115.58% from a year prior.
  • Revenue hit $1.1 million in Q4 2025 for Insight Molecular Diagnostics, up from $260000.0 in the prior quarter.
  • Over the last five years, Revenue for IMDX hit a ceiling of $3.6 million in Q4 2021 and a floor of $67000.0 in Q3 2022.
  • Historically, Revenue has averaged $806200.0 across 5 years, with a median of $404500.0 in 2022.
  • Biggest five-year swings in Revenue: soared 6925.0% in 2021 and later crashed 93.19% in 2022.
  • Tracing IMDX's Revenue over 5 years: stood at $3.6 million in 2021, then tumbled by 92.37% to $274000.0 in 2022, then rose by 14.6% to $314000.0 in 2023, then skyrocketed by 373.25% to $1.5 million in 2024, then decreased by 23.35% to $1.1 million in 2025.
  • Business Quant data shows Revenue for IMDX at $1.1 million in Q4 2025, $260000.0 in Q3 2025, and $518000.0 in Q2 2025.